Cytokinetics Initiates Phase 1 Clinical Study of CK-4021586
- ByInvesting.com-
Cytokinetics (NASDAQ:CYTK), Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled,...